MA40318A - Procédés de transduction et de traitement de cellules - Google Patents

Procédés de transduction et de traitement de cellules

Info

Publication number
MA40318A
MA40318A MA040318A MA40318A MA40318A MA 40318 A MA40318 A MA 40318A MA 040318 A MA040318 A MA 040318A MA 40318 A MA40318 A MA 40318A MA 40318 A MA40318 A MA 40318A
Authority
MA
Morocco
Prior art keywords
methods
treatment
chamber
transduction
cells
Prior art date
Application number
MA040318A
Other languages
English (en)
Inventor
Ryan L Crisman
Chris Ramsborg
Travis Wood
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of MA40318A publication Critical patent/MA40318A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B04—CENTRIFUGAL APPARATUS OR MACHINES FOR CARRYING-OUT PHYSICAL OR CHEMICAL PROCESSES
    • B04B—CENTRIFUGES
    • B04B7/00—Elements of centrifuges
    • B04B7/08—Rotary bowls
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)

Abstract

L'invention porte sur des procédés, des systèmes et des kits pour le traitement cellulaire, par exemple pour un usage thérapeutique, par exemple pour une thérapie cellulaire adoptive. Les procédés fournis comprennent des procédés de transduction dans lesquels des cellules et des virus sont incubés dans des conditions qui entraînent la transduction des cellules avec un vecteur viral. L'incubation dans certains modes de réalisation est réalisée dans une cavité interne d'une chambre centrifuge généralement rigide, telle qu'une chambre cylindrique en plastique dur dont la cavité peut avoir un volume variable. Les procédés comprennent d'autres étapes de traitement, y compris celles réalisées dans une telle chambre, y compris le lavage, la sélection, l'isolement, la culture et la formulation. En particulier, la description concerne un procédé fournissant des avantages par rapport aux procédés de traitement disponibles, tels que les procédés disponibles pour un traitement à grande échelle. De tels avantages comprennent, par exemple, un coût réduit, une rationalisation, une efficacité accrue, une sécurité accrue et une reproductibilité accrue entre différents sujets et conditions.
MA040318A 2014-11-05 2015-11-04 Procédés de transduction et de traitement de cellules MA40318A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462075801P 2014-11-05 2014-11-05
US201562129023P 2015-03-05 2015-03-05

Publications (1)

Publication Number Publication Date
MA40318A true MA40318A (fr) 2017-09-13

Family

ID=54754736

Family Applications (1)

Application Number Title Priority Date Filing Date
MA040318A MA40318A (fr) 2014-11-05 2015-11-04 Procédés de transduction et de traitement de cellules

Country Status (29)

Country Link
US (3) US10428351B2 (fr)
EP (3) EP4407036A3 (fr)
JP (4) JP6740234B2 (fr)
KR (2) KR102635942B1 (fr)
CN (2) CN107109438B (fr)
AU (3) AU2015343121B2 (fr)
BR (2) BR112017009220B1 (fr)
CA (1) CA2966538A1 (fr)
CY (1) CY1123254T1 (fr)
DK (2) DK3215601T3 (fr)
ES (2) ES2805674T3 (fr)
FI (1) FI3757206T3 (fr)
HR (1) HRP20201128T1 (fr)
HU (1) HUE050264T2 (fr)
IL (2) IL252126B (fr)
LT (1) LT3215601T (fr)
MA (1) MA40318A (fr)
MX (3) MX389108B (fr)
MY (1) MY186199A (fr)
NZ (2) NZ769598A (fr)
PH (1) PH12017500824A1 (fr)
PL (2) PL3757206T3 (fr)
PT (2) PT3215601T (fr)
RS (1) RS60685B1 (fr)
SG (2) SG10202002324SA (fr)
SI (1) SI3215601T1 (fr)
SM (1) SMT202000397T1 (fr)
TW (3) TW202315948A (fr)
WO (1) WO2016073602A2 (fr)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
JP6694875B2 (ja) 2014-05-15 2020-05-20 ナショナル ユニヴァーシティ オブ シンガポール 改変ナチュラルキラー細胞及びその使用
AU2015336029B2 (en) 2014-10-20 2021-07-22 Juno Therapeutics, Inc. Methods and compositions for dosing in adoptive cell therapy
FI3757206T3 (fi) 2014-11-05 2024-06-19 Juno Therapeutics Inc Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
US20170326278A1 (en) * 2014-12-19 2017-11-16 Biosafe S.A. Sequential processing of biological fluids
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée
HUE051661T2 (hu) 2015-05-18 2021-03-29 Tcr2 Therapeutics Inc Készítmények és gyógyászati felhasználások a TCR újraprogramozására fúziós fehérjék felhasználásával
RU2021134624A (ru) 2015-10-22 2022-03-15 Джуно Терапьютикс Гмбх Способы, наборы, средства и устройства для трансдукции
US20170198303A1 (en) 2015-12-04 2017-07-13 Emory University Methods, Devices and Systems for Enhanced Transduction Efficiency
AU2017229635A1 (en) * 2016-03-07 2018-09-20 Hitachi Chemical Advanced Therapeutics Solutions, LLC A closed system for labelling and selecting live cells
MA43759A (fr) 2016-03-16 2018-11-28 Jason Connor Procédés de conception adaptative d'un régime de traitement et traitements associés
US11111505B2 (en) 2016-03-19 2021-09-07 Exuma Biotech, Corp. Methods and compositions for transducing lymphocytes and regulating the activity thereof
US11325948B2 (en) 2016-03-19 2022-05-10 Exuma Biotech Corp. Methods and compositions for genetically modifying lymphocytes to express polypeptides comprising the intracellular domain of MPL
KR20230107408A (ko) 2016-07-29 2023-07-14 주노 쎄러퓨티크스 인코퍼레이티드 항-cd19 항체에 대한 항-이디오타입 항체
JP7109789B2 (ja) 2016-08-02 2022-08-01 ティーシーアール２ セラピューティクス インク． 融合タンパク質を使用したｔｃｒの再プログラム化のための組成物及び方法
WO2018049420A1 (fr) 2016-09-12 2018-03-15 Juno Therapeutics, Inc. Ensembles de poches de bioréacteur de perfusion
WO2018067993A1 (fr) 2016-10-07 2018-04-12 TCR2 Therapeutics Inc. Compositions et méthodes de reprogrammation des récepteurs des lymphocytes t faisant appel à des protéines de fusion
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
WO2018102761A1 (fr) * 2016-12-02 2018-06-07 City Of Hope Procédés de préparation et d'accroissement de lymphocytes t exprimant des récepteurs antigéniques chimériques et d'autres récepteurs
JP2019536461A (ja) * 2016-12-05 2019-12-19 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法のための操作細胞の産生
MX2019010171A (es) 2017-02-27 2019-10-15 Juno Therapeutics Inc Composiciones, articulos de fabricacion y metodos relacionados con la dosificacion en la terapia celular.
CN110913690A (zh) 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
KR102660336B1 (ko) 2017-03-27 2024-04-26 내셔널 유니버시티 오브 싱가포르 절단된 nkg2d 키메라 수용체 및 자연 살해 세포 면역요법에서의 그의 용도
MX2019011570A (es) 2017-03-27 2019-11-18 Nat Univ Singapore Lineas celulares estimuladoras para expansion y activacion ex vivo de celulas asesinas naturales.
EP3427052A4 (fr) * 2017-03-27 2019-12-04 Hitachi Chemical Advanced Therapeutics Solutions, LLC Système fermé pour le marquage et la sélection de cellules vivantes
JP2020522489A (ja) * 2017-06-02 2020-07-30 ジュノー セラピューティクス インコーポレイテッド 養子細胞療法を用いる処置のための製造物品および方法
MX2020000900A (es) 2017-07-29 2021-01-08 Juno Therapeutics Inc Reactivos para expandir celulas que expresan receptores recombinantes.
CN115216450A (zh) * 2017-09-01 2022-10-21 隆萨沃克斯维尔股份有限公司 端到端细胞治疗自动化
WO2019051335A1 (fr) 2017-09-07 2019-03-14 Juno Therapeutics, Inc. Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
WO2019089858A2 (fr) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Procédés d'évaluation ou de surveillance d'une réponse à une thérapie cellulaire
EP4512823A3 (fr) * 2017-11-01 2025-05-14 Juno Therapeutics, Inc. Procédé de génération de compositions thérapeutiques de cellules modifiées
BR112020008565A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc processo para a produção de uma composição de célula t
KR20200095487A (ko) 2017-11-10 2020-08-10 주노 쎄러퓨티크스 인코퍼레이티드 폐쇄-시스템 극저온 용기
CN119193493A (zh) 2017-12-08 2024-12-27 朱诺治疗学股份有限公司 生产工程化t细胞组合物的过程
CN112041430A (zh) 2017-12-08 2020-12-04 朱诺治疗学股份有限公司 用于培养细胞的无血清培养基配制品及其使用方法
AU2018379094B2 (en) 2017-12-08 2025-09-25 Juno Therapeutics, Inc. Phenotypic markers for cell therapy and related methods
US11464800B2 (en) 2018-02-09 2022-10-11 Immatics US, Inc. Methods for manufacturing T cells
US12258381B2 (en) 2018-02-09 2025-03-25 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
CN112055717B (zh) 2018-04-02 2024-04-26 新加坡国立大学 用在免疫细胞中表达的膜结合抗细胞因子非信号传导粘合剂中和人细胞因子
WO2020033916A1 (fr) 2018-08-09 2020-02-13 Juno Therapeutics, Inc. Procédés pour évaluer des acides nucléiques intégrés
IL280659B2 (en) 2018-08-09 2024-11-01 Juno Therapeutics Inc Processes for generating engineered cells and compositions thereof
CN112601758A (zh) 2018-08-29 2021-04-02 新加坡国立大学 特异性刺激经基因修饰免疫细胞的存活和扩增的方法
AU2019339464A1 (en) 2018-09-11 2021-03-25 Juno Therapeutics, Inc. Methods for mass spectrometry analysis of engineered cell compositions
JP7396777B2 (ja) 2018-09-28 2023-12-12 オクタン バイオテック インコーポレーテッド 磁気分離
CN113227358A (zh) 2018-10-31 2021-08-06 朱诺治疗学有限公司 选择并刺激细胞的方法及用于所述方法的设备
IL282735B2 (en) 2018-11-01 2025-10-01 Gracell Biotechnologies Shanghai Co Ltd Preparations and methods for engineering T cells
AU2019372331A1 (en) 2018-11-01 2021-05-27 Juno Therapeutics, Inc. Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen
MX2021005021A (es) 2018-11-06 2021-08-11 Juno Therapeutics Inc Proceso para producir celulas t geneticamente modificadas.
JP2022008735A (ja) * 2018-11-06 2022-01-14 テルモ株式会社 細胞製造システム、細胞製造方法、医療装置及び医療デバイス
KR20210104713A (ko) 2018-11-16 2021-08-25 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ 세포 악성 종양 치료를 위한 조작된 ｔ 세포 투약 방법
FI3886875T3 (fi) 2018-11-30 2024-07-23 Juno Therapeutics Inc Adoptiivista soluterapiaa käyttäviä hoitomenetelmiä
BR112021010120A2 (pt) 2018-11-30 2021-08-31 Juno Therapeutics, Inc. Métodos para dosagem e tratamento de malignidades celulares em terapia celular adotiva
CN118931967A (zh) * 2018-12-07 2024-11-12 亘喜生物科技（上海）有限公司 用于免疫疗法的组合物和方法
WO2020132177A1 (fr) 2018-12-21 2020-06-25 Lonza Walkersville, Inc. Production automatisée de vecteurs viraux
CA3123314A1 (fr) 2018-12-21 2020-06-25 Octane Biotech Inc. Carrousel pour unites de production biologique modulaires
US11773365B2 (en) 2019-02-08 2023-10-03 Lonza Walkersville, Inc. Cell concentration methods and devices for use in automated bioreactors
SG11202109057XA (en) 2019-03-05 2021-09-29 Nkarta Inc Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
JPWO2020196412A1 (fr) * 2019-03-26 2020-10-01
CN114207136A (zh) 2019-06-07 2022-03-18 朱诺治疗学股份有限公司 自动化t细胞培养
CN113785049B (zh) 2019-06-10 2025-11-25 爱平世股份有限公司 细胞培养方法及单核细胞的回收方法
KR20220034782A (ko) 2019-06-12 2022-03-18 주노 쎄러퓨티크스 인코퍼레이티드 세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
CN114555112A (zh) 2019-08-22 2022-05-27 朱诺治疗学股份有限公司 T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
WO2021041994A2 (fr) 2019-08-30 2021-03-04 Juno Therapeutics, Inc. Procédés d'apprentissage automatique pour la classification de cellules
BR112022007637A2 (pt) 2019-10-21 2022-07-12 Flaskworks Llc Sistemas e métodos para cultura de células
CA3158797A1 (fr) 2019-10-24 2021-04-29 Octane Biotech Inc. Chambre de culture cellulaire presentant des surfaces de contact cellulaire ameliorees
BR112022008023A2 (pt) 2019-10-30 2022-07-12 Juno Therapeutics Gmbh Dispositivos de seleção e/ou estimulação de células e métodos de uso
EP4055383A1 (fr) 2019-11-05 2022-09-14 Juno Therapeutics, Inc. Procédés de détermination d'attributs de compositions de cellules t thérapeutiques
EP4058563A4 (fr) 2019-11-11 2023-12-06 Lonza Walkersville, Inc. Procédés de contrôle qualité pour le traitement automatisé de cellules
US12570749B2 (en) 2019-12-06 2026-03-10 Juno Therapeutics, Inc. Anti-idiotypic antibodies to GPRC5D-targeted binding domains and related compositions and methods
EP4070097A1 (fr) 2019-12-06 2022-10-12 Juno Therapeutics, Inc. Procédés liés à la toxicité et à la réponse associées à une thérapie cellulaire pour le traitement de tumeurs malignes des lymphocytes b
CN115916817A (zh) 2019-12-06 2023-04-04 朱诺治疗学股份有限公司 针对bcma靶向结合结构域的抗独特型抗体及相关组合物和方法
US20240182920A1 (en) * 2020-01-22 2024-06-06 Carsgen Therapeutics Co., Ltd. Method for transducing cells with viral vector
BR112022014501A2 (pt) 2020-01-24 2022-09-20 Juno Therapeutics Inc Métodos para dosagem e tratamento de linfoma folicular e linfoma de zona marginal em terapia celular adotiva
KR20220146480A (ko) 2020-01-28 2022-11-01 주노 쎄러퓨티크스 인코퍼레이티드 Ｔ 세포 형질도입 방법
MX2022009068A (es) 2020-02-06 2022-10-27 Cutiss Ag Dispositivo y método de aislamiento celular.
IL295381A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc bcma-directed chimeric t-cell antigen receptor compounds and methods and uses thereof
IL295384A (en) 2020-02-12 2022-10-01 Juno Therapeutics Inc Cd19-directed chimeric antigen receptor t cell compositions and methods and uses thereof
CN115885036A (zh) * 2020-04-03 2023-03-31 米伦纽姆医药公司 提高的病毒转导效率
AU2021251265A1 (en) 2020-04-10 2022-11-03 Juno Therapeutics, Inc. Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting B-cell maturation antigen
EP4150640A1 (fr) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Procédés d'identification de caractéristiques associées à une réponse clinique et leurs utilisations
EP4150057A2 (fr) 2020-05-13 2023-03-22 Juno Therapeutics, Inc. Procédé de production de lots de cellules donneuses exprimant un récepteur recombinant
KR20230095918A (ko) 2020-08-05 2023-06-29 주노 쎄러퓨티크스 인코퍼레이티드 Ror1-표적 결합 도메인에 대한 항이디오타입 항체 및 관련 조성물 및 방법
WO2022133030A1 (fr) 2020-12-16 2022-06-23 Juno Therapeutics, Inc. Polythérapie de thérapie cellulaire et d'inhibiteur de bcl2
TW202241469A (zh) 2021-02-20 2022-11-01 美商凱特製藥公司 免疫療法
JP2024511420A (ja) 2021-03-22 2024-03-13 ジュノー セラピューティクス インコーポレイテッド ウイルスベクター粒子の効力を評価する方法
EP4314814A1 (fr) 2021-03-22 2024-02-07 Juno Therapeutics, Inc. Procédés de détermination de la puissance d'une composition de cellules thérapeutiques
BR112023019847A2 (pt) 2021-03-29 2023-11-07 Juno Therapeutics Inc Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car
KR20240018454A (ko) 2021-05-06 2024-02-13 주노 테라퓨틱스 게엠베하 T 세포의 자극 및 형질도입 방법
KR20230173179A (ko) 2021-05-14 2023-12-26 카이트 파마 인코포레이티드 키메라 항원 수용체 t세포 요법
WO2023159001A1 (fr) 2022-02-15 2023-08-24 Kite Pharma, Inc. Prédiction d'événements indésirables à partir d'une immunothérapie
KR20250011945A (ko) 2022-05-17 2025-01-22 우모자 바이오파마 인코포레이티드 바이러스 입자의 제조
WO2023230581A1 (fr) 2022-05-25 2023-11-30 Celgene Corporation Procédés de fabrication de thérapies par lymphocytes t
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
EP4543923A1 (fr) 2022-06-22 2025-04-30 Juno Therapeutics, Inc. Méthodes de traitement pour thérapie de deuxième ligne par cellules car-t ciblées par cd19
TW202434735A (zh) 2022-11-04 2024-09-01 美商烏莫賈生物製藥股份有限公司 展示黏著分子融合的顆粒
IL320495A (en) 2022-11-04 2025-06-01 Umoja Biopharma Inc Construction of polynucleotide vectors and related viral methods
EP4630782A1 (fr) 2022-12-09 2025-10-15 Juno Therapeutics, Inc. Procédés d'apprentissage automatique pour prédire un phénotype cellulaire au moyen d'une imagerie holographique
WO2024145732A1 (fr) * 2023-01-03 2024-07-11 深圳华大生命科学研究院 Système fluidique de triage et dispositif connexe, procédé de triage fluidique, et procédé de triage cellulaire
KR20260005874A (ko) 2023-02-28 2026-01-12 주노 쎄러퓨티크스 인코퍼레이티드 전신 자가면역 질환을 치료하기 위한 세포 요법
CN121311765A (zh) 2023-04-18 2026-01-09 朱诺治疗学股份有限公司 评估治疗性细胞组合物的效力的细胞毒性测定
WO2024226858A1 (fr) 2023-04-26 2024-10-31 Juno Therapeutics, Inc. Procédés de fabrication de vecteurs viraux
WO2024238153A1 (fr) 2023-05-15 2024-11-21 Umoja Biopharma, Inc. Administration lentivirale de récepteurs antigéniques chimériques anti-cd20
KR20260026101A (ko) 2023-05-23 2026-02-25 주노 쎄러퓨티크스 인코퍼레이티드 T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
WO2025231174A1 (fr) 2024-04-30 2025-11-06 Umoja Biopharma, Inc. Fabrication de particules virales
WO2025235604A1 (fr) 2024-05-08 2025-11-13 Umoja Biopharma, Inc. Protéine de fusion destinée à être utilisée en tant qu'engageur de cellules immunitaires
WO2026020055A2 (fr) 2024-07-18 2026-01-22 Juno Therapeutics, Inc. Procédés d'évaluation d'exosomes dans une composition cellulaire et utilisations associées

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4163519A (en) 1977-11-01 1979-08-07 Union Carbide Corporation Compensating rotor
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
SE454413B (sv) 1986-09-12 1988-05-02 Alfa Laval Separation Ab Centrifugalseparator med en rotor, vari ett bojligt organ strecker sig ett stycke lengs rotorns omkrets
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990007380A2 (fr) 1988-12-28 1990-07-12 Stefan Miltenyi Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
AU650085B2 (en) 1990-11-13 1994-06-09 Immunex Corporation Bifunctional selectable fusion genes
US5911983A (en) * 1992-06-26 1999-06-15 University Of Pittsburgh Gene therapy for Gaucher disease using retroviral vectors
EP0804590A1 (fr) 1993-05-21 1997-11-05 Targeted Genetics Corporation Genes de fusion selectables et bifonctionnels se basant sur le gene de cytosine-deaminase (cd)
US5437998A (en) * 1993-09-09 1995-08-01 Synthecon, Inc. Gas permeable bioreactor and method of use
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
AU1333797A (en) 1995-12-15 1997-07-03 Systemix, Inc. Method for obtaining retroviral vector supernatant having high transduction efficiency
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
WO1997034634A1 (fr) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Produits de recombinaison d'anticorps diriges contre le gd2, constitues d'un fragment variable (fv) a chaine simple
AU6467796A (en) * 1996-04-24 1997-05-15 Claude Fell Cell separation system for biological fluids like blood
EP0995802B1 (fr) 1998-07-10 2009-12-23 Universite Pierre Et Marie Curie Procédé pour l'apport des acides nucléiques dans les cellules in vitro ou ex vivo
EP1109921A4 (fr) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
CN1182882C (zh) 1998-12-24 2005-01-05 生物安全股份有限公司 特别用于浓缩造血干细胞的血液分离系统
US20030119185A1 (en) * 2000-02-24 2003-06-26 Xcyte Therapies, Inc. Activation and expansion of cells
CA2410510A1 (fr) 2000-06-02 2001-12-13 Memorial Sloan-Kettering Cancer Center Cellules presentatrices d'antigene artificiel et leurs methodes d'utilisation
EP1334188B1 (fr) 2000-11-07 2006-08-30 City of Hope Cellules immunitaires specifiques a cd19 redirigees
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
DE10136375A1 (de) 2001-07-26 2003-02-13 Cellgenix Technologie Transfer Verfahren zur Anreicherung von Zellen
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
US7001513B2 (en) 2003-08-06 2006-02-21 Nuvue Technologies, Inc. Automated processing of a biological component
US7435596B2 (en) 2004-11-04 2008-10-14 St. Jude Children's Research Hospital, Inc. Modified cell line and method for expansion of NK cell
EP1893253B1 (fr) 2005-03-23 2010-05-19 Biosafe S.A. Systeme integre permettant de recueillir, traiter et transplanter des sous-ensembles de cellules, y compris des cellules souches adultes, pour la medecine regenerative
JP5453629B2 (ja) 2006-08-23 2014-03-26 タカラバイオ株式会社 遠心用袋状容器を使用した遺伝子導入方法
DK2141997T3 (da) 2007-03-30 2013-02-11 Sloan Kettering Inst Cancer Konstitutiv ekspression af co-stimulatoriske ligander på adoptivt overførte t-lymfocytter
US8747290B2 (en) 2007-12-07 2014-06-10 Miltenyi Biotec Gmbh Centrifuge for separating a sample into at least two components
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
WO2010008579A2 (fr) * 2008-07-16 2010-01-21 Kbi Biopharma, Inc. Procédés et systèmes de manipulation de particules au moyen d'un lit fluidisé
HUE044461T2 (hu) 2009-11-03 2019-10-28 Hope City Csonkolt epidermális növekedési faktor receptor (EGFRT) transzdukált T-sejt szelekcióhoz
MY160835A (en) 2010-03-18 2017-03-31 Syngen Inc System for purifying certain cell populations in blood or bone marrow by depleting others
SE535275C2 (sv) 2010-03-31 2012-06-12 Alfa Laval Corp Ab Centrifugalseparator och rotor
JP5793567B2 (ja) * 2010-07-15 2015-10-14 テルモ ビーシーティー、インコーポレーテッド 生体液用の遠心分離装置において回転時間を最適化するための方法
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CA2824997C (fr) * 2011-01-18 2023-01-17 The Trustees Of The University Of Pennsylvania Compositions et procedes de traitement du cancer
AU2012230780B2 (en) 2011-03-23 2016-10-27 Fred Hutchinson Cancer Center Method and compositions for cellular immunotherapy
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US9969966B2 (en) * 2011-05-30 2018-05-15 Atech Partners Limited Bioreactor system for continuous cell cultivation
CN102329776B (zh) * 2011-07-20 2013-02-27 华中农业大学 一种表达Nectin-1基因胞外区片段的PK-15细胞系及其构建方法
KR101956751B1 (ko) * 2011-10-07 2019-03-11 고쿠리츠다이가쿠호진 미에다이가쿠 키메라 항원 수용체
AU2012335073B2 (en) 2011-11-11 2017-08-17 Fred Hutchinson Cancer Center Cyclin A1-targeted T-cell immunotherapy for cancer
EP2594632A1 (fr) * 2011-11-18 2013-05-22 Miltenyi Biotec GmbH Procédé et dispositif de modification cellulaire
US9447194B2 (en) 2012-02-13 2016-09-20 Seattle Children's Hospital Bispecific chimeric antigen receptors and encoding polynucleotides thereof
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
US10228312B2 (en) * 2012-02-23 2019-03-12 Juno Therapeutics Gmbh Chromatographic isolation of cells and other complex biological materials
DK2820138T3 (da) 2012-02-29 2020-12-07 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum Gesundheit & Umwelt Gmbh Retroviral transduktion under anvendelse af poloxamerer
CN104160019A (zh) 2012-03-13 2014-11-19 Emd密理博公司 使用离心辅助的感染以增加病毒滴度
NZ702108A (en) 2012-05-03 2016-09-30 Hutchinson Fred Cancer Res Enhanced affinity t cell receptors and methods for making the same
DK3473707T3 (da) * 2012-05-25 2025-03-17 Cellectis Fremgangsmåder til engineering af allogen og immunsuppressiv resistent t-celle til immunoterapi
EP2698208A1 (fr) 2012-08-14 2014-02-19 Fresenius Kabi Deutschland GmbH Dispositif de centrifugation et procédé de fonctionnement dýun dispositif de centrifugation
PT3824905T (pt) 2012-08-20 2025-03-21 Seattle Childrens Hospital Dba Seattle Childrens Res Inst Método e composições para imunoterapêutica celular
MX370148B (es) 2012-10-02 2019-12-03 Memorial Sloan Kettering Cancer Center Composiciones y su uso para inmunoterapia.
DE112012007250B4 (de) 2012-12-20 2024-10-24 Mitsubishi Electric Corp. Fahrzeuginterne Vorrichtung und Programm
CA2904369A1 (fr) * 2013-03-07 2014-09-12 Baylor College Of Medicine Ciblage de cd138 dans le cancer
UY35468A (es) * 2013-03-16 2014-10-31 Novartis Ag Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
PT2981607T (pt) * 2013-04-03 2020-11-20 Memorial Sloan Kettering Cancer Center Geração eficaz de células t direcionadas a tumores, derivadas de células estaminais pluripotentes
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
KR20160079854A (ko) 2013-10-31 2016-07-06 프레드 헛친슨 켄서 리서치 센터 변형된 조혈 줄기/선조 및 비-t 효과기 세포 및 이의 용도
MA39867A (fr) 2014-04-23 2017-03-01 Juno Therapeutics Inc Procédés d'isolement, de culture et de manipulation génétique de populations de cellules immunitaires pour une thérapie adoptive
CN106062185A (zh) 2014-04-24 2016-10-26 美天旎生物技术有限公司 用于自动生成遗传修饰的t细胞的方法
FI3757206T3 (fi) 2014-11-05 2024-06-19 Juno Therapeutics Inc Menetelmiä transduktoimiseksi ja solun prosessoimiseksi
MA41346A (fr) 2015-01-12 2017-11-21 Juno Therapeutics Inc Eléments régulateurs post-transcriptionnels d'hépatite modifiée

Also Published As

Publication number Publication date
IL252126B (en) 2022-06-01
JP2017535282A (ja) 2017-11-30
BR112017009220B1 (pt) 2022-04-12
EP3757206A1 (fr) 2020-12-30
PH12017500824A1 (en) 2017-10-18
PL3215601T3 (pl) 2020-11-02
AU2020233623B2 (en) 2022-08-04
HRP20201128T1 (hr) 2020-10-30
SG11201703656PA (en) 2017-06-29
TWI735418B (zh) 2021-08-11
TWI787903B (zh) 2022-12-21
MY186199A (en) 2021-06-30
PT3757206T (pt) 2024-05-21
TW202315948A (zh) 2023-04-16
KR20240023204A (ko) 2024-02-20
RS60685B1 (sr) 2020-09-30
ES2805674T3 (es) 2021-02-15
US20160122782A1 (en) 2016-05-05
US20240011051A1 (en) 2024-01-11
CN107109438B (zh) 2021-09-03
NZ732130A (en) 2021-11-26
KR102635942B1 (ko) 2024-02-14
US10428351B2 (en) 2019-10-01
CA2966538A1 (fr) 2016-05-12
EP4407036A2 (fr) 2024-07-31
IL292450A (en) 2022-06-01
JP2020182488A (ja) 2020-11-12
EP3757206B1 (fr) 2024-04-10
CN113736828A (zh) 2021-12-03
IL252126A0 (en) 2017-07-31
FI3757206T3 (fi) 2024-06-19
WO2016073602A3 (fr) 2016-06-30
JP2023024691A (ja) 2023-02-16
DK3215601T3 (da) 2020-06-15
MX2017005823A (es) 2017-08-02
DK3757206T3 (da) 2024-07-15
PL3757206T3 (pl) 2024-07-08
TW201636427A (zh) 2016-10-16
AU2015343121A1 (en) 2017-05-18
NZ769598A (en) 2023-05-26
MX389108B (es) 2025-03-20
CN107109438A (zh) 2017-08-29
TW202208633A (zh) 2022-03-01
NZ769595A (en) 2023-06-30
HUE050264T2 (hu) 2020-11-30
SG10202002324SA (en) 2020-05-28
WO2016073602A2 (fr) 2016-05-12
LT3215601T (lt) 2020-08-25
BR122020002722B1 (pt) 2022-06-07
MX2022000159A (es) 2022-02-21
BR112017009220A2 (pt) 2017-12-26
KR20170092567A (ko) 2017-08-11
AU2015343121B2 (en) 2020-06-18
SMT202000397T1 (it) 2020-09-10
AU2022263539A1 (en) 2023-02-23
JP2024159813A (ja) 2024-11-08
PT3215601T (pt) 2020-08-03
CY1123254T1 (el) 2021-10-29
US20190376084A1 (en) 2019-12-12
SI3215601T1 (sl) 2020-08-31
EP4407036A3 (fr) 2024-10-23
ES2987570T3 (es) 2024-11-15
JP7202332B2 (ja) 2023-01-11
US11802295B2 (en) 2023-10-31
AU2020233623A1 (en) 2020-10-08
JP6740234B2 (ja) 2020-08-12
MX2021001334A (es) 2021-04-12
AU2022263539B2 (en) 2024-12-05
EP3215601A2 (fr) 2017-09-13
EP3215601B1 (fr) 2020-05-27

Similar Documents

Publication Publication Date Title
MA40318A (fr) Procédés de transduction et de traitement de cellules
WO2020123301A3 (fr) Génération de réseaux spatiaux avec des gradients
EA201792441A2 (ru) Домены фибронектина типа iii, связывающиеся с простатспецифическим мембранным антигеном
EP4306636A3 (fr) Monocouche de cmsp ou de cellules de moelle osseuse et utilisations associées
BR112017016897A2 (pt) cepas fúngicas e métodos de uso
MX2017008338A (es) Metodos de cultivo de una celula de mamifero.
CA3019753C (fr) Procede de culture cellulaire
Caro-Lopera et al. Matrix-variate distribution theory under elliptical models-4: Joint distribution of latent roots of covariance matrix and the largest and smallest latent roots
BR112019008774A2 (pt) método de preparação de extrato de cereal
EA201892117A1 (ru) Неразрушающее генотипирование семян
WO2016037036A3 (fr) Procédés de détection d'oligomères bêta-amyloïdes
FR3032448B1 (fr) Enrichissement et culture selective de mycobacteries
Carman Unit groups of representation rings and their ghost rings as inflation functors
Rdzanek et al. The low frequency axisymmetric modal sound radiation efficiency of an elastically supported annular plate
Kubiciel et al. Article 28: Knowledge, intent and purpose as elements of an offence
LANLAN The Xujiahui Legacy
RU2015147257A (ru) Устройство для выделения клеточных фракций из тканей человека и животных и способ его применения
Phuong et al. MECHANICAL STRETCH ALTERS THE EXPRESSION PROFILE OF MECHANOSENSITIVE CHANNELS IN MOUSE RETINAL GANGLION CELLS VIA ACTIVATION OF TRPV4
HATTORI et al. Detection of zoospores of the red rot disease fungus Pythium porphyrae by PCR in seawater from Porphyra cultivation farms at aichi prefecture in 2004 and 2005
RU2015148532A (ru) Способ дифференциации энтерококков кишечной микрофлоры животных
Allred et al. Susceptibility Of S49 Lymphoma Cell Membranes To Hydrolysis By Secretory Phospholipase A2 During Early Phase Of Apoptosis
WO2020222703A3 (fr) Dispositif d'ensemencement de cellules de dispersion
Yakovleva et al. Trematode Apophallus muehlingi (Jagerskiold, 1899) Luhe, 1909 in gulls in Northwest Russia.
Vodret et al. Application of a real-time PCR method for the detection of celery (Apium graveolens) in food [Conference poster].
WILLIAMS et al. VISIONS: the art of science